$116 Million is the total value of Opus Point Partners Management, LLC's 65 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 400.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SAGE | New | SAGE THERAPEUTICS INCput | $11,694,000 | – | 71,000 | +100.0% | 10.12% | – |
| IBB | Buy | ISHARES TRnasdaq biotech | $4,004,000 | -4.0% | 37,500 | +200.0% | 3.46% | -7.4% |
| PRQR | New | PROQR THRAPEUTICS N V | $992,000 | – | 307,692 | +100.0% | 0.86% | – |
| IQV | New | IQVIA HLDGS INC | $236,000 | – | 2,415 | +100.0% | 0.20% | – |
| FGEN | New | FIBROGEN INC | $210,000 | – | 4,423 | +100.0% | 0.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.